Iovance Biotherapeutics, Inc.
IOVA
$3.06
-$0.01-0.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 16.18% | 5.31% | -5.10% | -9.23% | -12.16% |
| Total Depreciation and Amortization | 31.63% | 42.97% | 65.09% | 70.85% | 56.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 76.49% | 21.43% | -7.41% | -29.03% | -34.49% |
| Change in Net Operating Assets | -1,779.40% | -371.82% | -412.18% | -383.44% | -125.48% |
| Cash from Operations | 2.44% | -2.29% | -16.02% | -20.55% | -23.59% |
| Capital Expenditure | 50.34% | 52.12% | 40.19% | -41.97% | -9.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 75.28% | 75.42% | 73.42% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -141.13% | -185.24% | -151.93% | -139.69% | -71.22% |
| Cash from Investing | 37.90% | -135.47% | -415.21% | -229.94% | -160.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -13.36% | -38.72% | 23.04% | -10.53% | 141.57% |
| Repurchase of Common Stock | -360.04% | -366.23% | -180.99% | -21.60% | -5.51% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -15.62% | -40.34% | 22.26% | -10.86% | 143.47% |
| Foreign Exchange rate Adjustments | 80.26% | 163.50% | 110.93% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.26% | -178.15% | -133.71% | -190.66% | -136.95% |